Antifungal İlaç Zehirlenmeleri

Rex, J.H., et al., A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med, 1994. 331(20): p. 1325-30.

Kontoyiannis, D.P. and R.E. Lewis, Antifungal drug resistance of pathogenic fungi. Lancet, 2002. 359(9312): p. 1135-44.

Prentice, A.G. and A. Glasmacher, Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother, 2005. 56 Suppl 1: p. i17-i22.

Herbrecht, R., et al., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 2002. 347(6): p. 408-15.

Kauffman, C.A., et al., Posaconazole. Nat Rev Drug Discov, 2007. 6(3): p. 183-4.

Rachwalski, E.J., J.T. Wieczorkiewicz, and M.H. Scheetz, Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother, 2008. 42(10): p. 1429-38.

Wingard, J.R., et al., Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010. 116(24): p. 5111-8.

Ullmann, A.J., et al., Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med, 2007. 356(4): p. 335-47.

Girmenia, C., New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs, 2009. 18(9): p. 1279-95.

Pappas, P.G., et al., Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis, 2007. 45(7): p. 883-93.

Sheehan, D.J., C.A. Hitchcock, and C.M. Sibley, Current and emerging azole antifungal agents. Clin Microbiol Rev, 1999. 12(1): p. 40-79.

Odds, F.C., A.J. Brown, and N.A. Gow, Antifungal agents: mechanisms of action. Trends Microbiol, 2003. 11(6): p. 272-9.

Mann, P.A., et al., Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother, 2003. 47(2): p. 577-81.

Ryder, N.S., Activity of terbinafine against serious fungal pathogens. Mycoses, 1999. 42 Suppl 2: p. 115-119.

Brajtburg, J., et al., Amphotericin B: delivery systems. Antimicrob Agents Chemother, 1990. 34(3): p. 381-4.

Groll, A.H., S.C. Piscitelli, and T.J. Walsh, Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol, 1998. 44: p. 343-500.

Cleary, J.D., P.D. Rogers, and S.W. Chapman, Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy, 2003. 23(5): p. 572-8.

Saliba, F. and B. Dupont, Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol, 2008. 46(2): p. 97-112.

Chamilos, G. and D.P. Kontoyiannis, Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat, 2005. 8(6): p. 344-58.

Douglas, C.M., et al., Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother, 1997. 41(11): p. 2471-9.

Diasio, R.B., J.E. Bennett, and C.E. Myers, Mode of action of 5-fluorocytosine. Biochem Pharmacol, 1978. 27(5): p. 703-7.

Johnston, A., The pharmacokinetics of voriconazole. Br J Clin Pharmacol, 2003. 56 Suppl 1(Suppl 1): p. 1.

Krishna, G., et al., Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother, 2009. 53(3): p. 958-66.

Walsh, T.J., et al., Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother, 2010. 54(10): p. 4116-23.

Brüggemann, R.J., et al., Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis, 2009. 48(10): p. 1441-58.

Lewis, R.E., Managing drug interactions in the patient with aspergillosis. Med Mycol, 2006. 44(Supplement_1): p. S349-s356.

Saad, A.H., D.D. DePestel, and P.L. Carver, Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy, 2006. 26(12): p. 1730-44.

Imai, J.K., et al., Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother, 2004. 48(10): p. 4063-6.

Tucker, R.M., et al., Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis, 1992. 14(1): p. 165-74.

Araz, C., et al., Evaluating the poisoning cases in Ümraniye Training and Research Hospital Pediatric Emergency Department. Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2017. 13: p. 57-67.